ITRM Reports Results

Iterum Therapeutics Plc (NASDAQ:ITRM), an infectious disease biopharma company preparing to launch a new oral antibiotic for urinary tract infections, reported its results for the second quarter of 2025 on August 5, 2025. The key news in the release was its continued lack of revenue as it gears up for the first commercial sales of ORLYNVAH™, coupled with a larger operating loss driven by a jump in general and administrative costs. Reported non-GAAP loss per share came in at ($0.13), which was $0.02 below analyst expectations for non-GAAP EPS, while revenue (GAAP) was in line with estimates at zero. Overall, the quarter marked a pivotal transition phase, with significant expense increases for launch readiness but progress made in manufacturing, patent protection, and financial runway extension.

Source: Analyst estimates provided by FactSet. Management expectations based on management's guidance, as provided in Q1 2025 earnings report.

Iterum Therapeutics focuses on bringing new solutions to patients with serious infectious diseases, especially those where antibiotic resistance limits treatment options. Its most advanced product is ORLYNVAH™, an oral antibiotic tablet aimed at treating uncomplicated urinary tract infections (uUTIs), particularly cases caused by bacteria resistant to existing drugs.

Continue reading

Source Fool.com